Plain-English translation of NCT04778046 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is looking for a fingerprint — visible on a special type of MRI scan — that shows when the blood vessels in your lungs have changed in a particular way. Researchers want to understand whether people with conditions like pulmonary fibrosis or COPD who also have high blood pressure in their lungs might have the same blood vessel changes as people with pulmonary arterial hypertension. If they do, they may respond better to medications like Tyvaso that are designed for that specific problem.
Some patients with advanced lung disease develop high blood pressure in their lung blood vessels, but we don't have a good way to tell which patients will respond to medications designed to treat this problem. This study aims to find a simple, non-invasive imaging test that could predict who will benefit from this medication and who won't — potentially saving patients from treatments that won't help them.
You likely qualify if…
You likely don't qualify if…
You would undergo a specialized MRI scan using a gas called xenon-129 that helps show how your lung blood vessels are structured and how well blood flow is working. The study compares different groups of people with different lung conditions to see if their blood vessel patterns look similar. You would be asked to come to Duke University Medical Center for study visits, and researchers would use the imaging results alongside your medical records to build a better understanding of who might respond to lung blood pressure medications.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States